FACULTY
Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati
Department of Internal Medicine
Division of Immunology, Allergy Section
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Editor in Chief, Journal of Asthma
Cincinnati, OH
Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA
PROGRAM OVERVIEW
This enduring MedGames is an interactive gamification-style CME activity that covers important topics in chronic spontaneous urticaria (CSU). The educational format of this program is engaging and covers the economic and physiological burden of CSU, diagnostic algorithms, guideline-recommended step-care management, and efficacy and safety of current and emerging biologic therapy.
TARGET AUDIENCE
The programming is intended for managed care pharmacists, pharmacy directors, physicians, and other health care providers involved in the management of patients with CSU.
LEARNING OBJECTIVES
On completing this program, attendees should be able to:
- Quantify the economic, physical, and psychosocial burden of chronic spontaneous urticaria (CSU)
- Assess treatment plans for adherence to guideline recommended therapy and consideration of patient-specific factors
- Evaluate clinical trial data on the efficacy and safety of available and emerging biologics for CSU
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in caring for patients with chronic spontaneous urticaria.
CNE Credits: 1.50 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.50 contact hours of continuing nursing education of RNs and APNs.
PHARMACY ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Jonathan A. Bernstein, MD, reports the following disclosures:
| Relationship | Manufacturer |
| Consultant | Amgen, AstraZeneca, Celldex, Genentech, Novartis, Genentech, Sanofi/Regeneron |
| Speaker Bureau | AstraZeneca, Genentech, Novartis, Sanofi/Regeneron |
| Contract Research | Amgen, AstraZeneca, Celldex, Genentech, Novartis, Genentech, Sanofi/Regeneron |
| Other commercial interest | AstraZeneca, Genentech, Novartis, Sanofi/Regeneron |
Geoffrey C. Wall, PharmD, FCCP, BCPS serves on the speaker bureau for Janssen Pharmaceuticals and Tetraphase Pharmaceuticals
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator has nothing to disclose.
- Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to the Med Learning Group.
You will receive your certification as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
